Triple-negative breast cancer (TNBC) is particularly challenging because of its lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), making it unresponsive to hormonal and HER2-targeted therapies. Here, ERBB2 is linked to triple-negative breast carcinoma.